Key facts
- This page summarizes Nchacha Etta's Form 4 filing for OMNICELL, INC. (OMCL).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Mar 2025, 16:26.
Nchacha Etta - 08 Mar 2025 Form 4 Insider Report for OMNICELL, INC. (OMCL)
- Reporting relationship
- EVP & CFO
- Issuer ticker
- OMCL
- Reported as of
- 08 Mar 2025
- Net transaction value
- -$198,562
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2025, 16:26:26 UTC
- Prior SEC filing
- 04 Mar 2025
- Next SEC filing
- 19 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vijay Biligiri, Attorney in-Fact for Nchacha Etta
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nchacha Etta filed Form 4 for OMNICELL, INC. (OMCL) on 11 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: -$198,562.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OMCL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +66,633
- Change %
- +94%
- Price
- $0.000000
- Shares after
- 137,391
- Date
- 08 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
OMCL
transaction
Common Stock
Tax liability
- Transaction value
- $198,562
- Shares
- -5,368
- Change %
- -3.9%
- Price
- $36.99
- Shares after
- 132,023
- Date
- 08 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects performance-based restricted stock units that were previously granted on February 27, 2024, subject to the Company meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index. On March 8, 2025 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 66,633 performance-based restricted stock units (176% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).
Footnote F2
Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.